PARP (Poly ADP-ribose Polymerase) Inhibitors Market, Global Outlook and Forecast 2022-2028

February 2022 | 61 pages | ID: P2BED07CC7A0EN
Market Monitor Global

Abstracts

PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoting apoptosis of tumor cells. Parp (Poly Adp-Ribose Polymerase) inhibitors is very effective in treating solid tumors and other diseases.Such as advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer.

This report contains market size and forecasts of PARP (Poly ADP-ribose Polymerase) Inhibitors in Global, including the following market information:

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global PARP (Poly ADP-ribose Polymerase) Inhibitors market was valued at 2943.8 million in 2021 and is projected to reach US$ 19900 million by 2028, at a CAGR of 31.4% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Olaparib Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of PARP (Poly ADP-ribose Polymerase) Inhibitors include AbbVie, Pfizer, AstraZeneca, GlaxoSmithKline, Clovis Oncology and Everest Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the PARP (Poly ADP-ribose Polymerase) Inhibitors companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Segment Percentages, by Type, 2021 (%)

• Olaparib
• Talazoparib

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Segment Percentages, by Application, 2021 (%)

• Ovarian Cancer
• Breast Cancer
• Other

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies PARP (Poly ADP-ribose Polymerase) Inhibitors revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies PARP (Poly ADP-ribose Polymerase) Inhibitors revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AbbVie
• Pfizer
• AstraZeneca
• GlaxoSmithKline
• Clovis Oncology
• Everest Pharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 PARP (Poly ADP-ribose Polymerase) Inhibitors Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITORS OVERALL MARKET SIZE

2.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size: 2021 VS 2028
2.2 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top PARP (Poly ADP-ribose Polymerase) Inhibitors Players in Global Market
3.2 Top Global PARP (Poly ADP-ribose Polymerase) Inhibitors Companies Ranked by Revenue
3.3 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue by Companies
3.4 Top 3 and Top 5 PARP (Poly ADP-ribose Polymerase) Inhibitors Companies in Global Market, by Revenue in 2021
3.5 Global Companies PARP (Poly ADP-ribose Polymerase) Inhibitors Product Type
3.6 Tier 1, Tier 2 and Tier 3 PARP (Poly ADP-ribose Polymerase) Inhibitors Players in Global Market
  3.6.1 List of Global Tier 1 PARP (Poly ADP-ribose Polymerase) Inhibitors Companies
  3.6.2 List of Global Tier 2 and Tier 3 PARP (Poly ADP-ribose Polymerase) Inhibitors Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size Markets, 2021 & 2028
  4.1.2 Olaparib
  4.1.3 Talazoparib
4.2 By Type - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue & Forecasts
  4.2.1 By Type - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2022
  4.2.2 By Type - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2023-2028
  4.2.3 By Type - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2021 & 2028
  5.1.2 Ovarian Cancer
  5.1.3 Breast Cancer
  5.1.4 Other
5.2 By Application - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue & Forecasts
  5.2.1 By Application - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2022
  5.2.2 By Application - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2023-2028
  5.2.3 By Application - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2021 & 2028
6.2 By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue & Forecasts
  6.2.1 By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2022
  6.2.2 By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2023-2028
  6.2.3 By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2028
  6.3.2 US PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.3.3 Canada PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.3.4 Mexico PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2028
  6.4.2 Germany PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.4.3 France PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.4.4 U.K. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.4.5 Italy PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.4.6 Russia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.4.7 Nordic Countries PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.4.8 Benelux PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2028
  6.5.2 China PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.5.3 Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.5.4 South Korea PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.5.5 Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.5.6 India PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2028
  6.6.2 Brazil PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.6.3 Argentina PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2028
  6.7.2 Turkey PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.7.3 Israel PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.7.4 Saudi Arabia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
  6.7.5 UAE PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AbbVie
  7.1.1 AbbVie Corporate Summary
  7.1.2 AbbVie Business Overview
  7.1.3 AbbVie PARP (Poly ADP-ribose Polymerase) Inhibitors Major Product Offerings
  7.1.4 AbbVie PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global Market (2017-2022)
  7.1.5 AbbVie Key News
7.2 Pfizer
  7.2.1 Pfizer Corporate Summary
  7.2.2 Pfizer Business Overview
  7.2.3 Pfizer PARP (Poly ADP-ribose Polymerase) Inhibitors Major Product Offerings
  7.2.4 Pfizer PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global Market (2017-2022)
  7.2.5 Pfizer Key News
7.3 AstraZeneca
  7.3.1 AstraZeneca Corporate Summary
  7.3.2 AstraZeneca Business Overview
  7.3.3 AstraZeneca PARP (Poly ADP-ribose Polymerase) Inhibitors Major Product Offerings
  7.3.4 AstraZeneca PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global Market (2017-2022)
  7.3.5 AstraZeneca Key News
7.4 GlaxoSmithKline
  7.4.1 GlaxoSmithKline Corporate Summary
  7.4.2 GlaxoSmithKline Business Overview
  7.4.3 GlaxoSmithKline PARP (Poly ADP-ribose Polymerase) Inhibitors Major Product Offerings
  7.4.4 GlaxoSmithKline PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global Market (2017-2022)
  7.4.5 GlaxoSmithKline Key News
7.5 Clovis Oncology
  7.5.1 Clovis Oncology Corporate Summary
  7.5.2 Clovis Oncology Business Overview
  7.5.3 Clovis Oncology PARP (Poly ADP-ribose Polymerase) Inhibitors Major Product Offerings
  7.5.4 Clovis Oncology PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global Market (2017-2022)
  7.5.5 Clovis Oncology Key News
7.6 Everest Pharmaceuticals
  7.6.1 Everest Pharmaceuticals Corporate Summary
  7.6.2 Everest Pharmaceuticals Business Overview
  7.6.3 Everest Pharmaceuticals PARP (Poly ADP-ribose Polymerase) Inhibitors Major Product Offerings
  7.6.4 Everest Pharmaceuticals PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global Market (2017-2022)
  7.6.5 Everest Pharmaceuticals Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Opportunities & Trends in Global Market
Table 2. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Drivers in Global Market
Table 3. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Restraints in Global Market
Table 4. Key Players of PARP (Poly ADP-ribose Polymerase) Inhibitors in Global Market
Table 5. Top PARP (Poly ADP-ribose Polymerase) Inhibitors Players in Global Market, Ranking by Revenue (2021)
Table 6. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Share by Companies, 2017-2022
Table 8. Global Companies PARP (Poly ADP-ribose Polymerase) Inhibitors Product Type
Table 9. List of Global Tier 1 PARP (Poly ADP-ribose Polymerase) Inhibitors Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 PARP (Poly ADP-ribose Polymerase) Inhibitors Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2023-2028
Table 30. AbbVie Corporate Summary
Table 31. AbbVie PARP (Poly ADP-ribose Polymerase) Inhibitors Product Offerings
Table 32. AbbVie PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), (2017-2022)
Table 33. Pfizer Corporate Summary
Table 34. Pfizer PARP (Poly ADP-ribose Polymerase) Inhibitors Product Offerings
Table 35. Pfizer PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), (2017-2022)
Table 36. AstraZeneca Corporate Summary
Table 37. AstraZeneca PARP (Poly ADP-ribose Polymerase) Inhibitors Product Offerings
Table 38. AstraZeneca PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), (2017-2022)
Table 39. GlaxoSmithKline Corporate Summary
Table 40. GlaxoSmithKline PARP (Poly ADP-ribose Polymerase) Inhibitors Product Offerings
Table 41. GlaxoSmithKline PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), (2017-2022)
Table 42. Clovis Oncology Corporate Summary
Table 43. Clovis Oncology PARP (Poly ADP-ribose Polymerase) Inhibitors Product Offerings
Table 44. Clovis Oncology PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), (2017-2022)
Table 45. Everest Pharmaceuticals Corporate Summary
Table 46. Everest Pharmaceuticals PARP (Poly ADP-ribose Polymerase) Inhibitors Product Offerings
Table 47. Everest Pharmaceuticals PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. PARP (Poly ADP-ribose Polymerase) Inhibitors Segment by Type in 2021
Figure 2. PARP (Poly ADP-ribose Polymerase) Inhibitors Segment by Application in 2021
Figure 3. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in 2021
Figure 8. By Type - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
Figure 9. By Application - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
Figure 10. By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
Figure 11. By Country - North America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
Figure 12. US PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 13. Canada PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
Figure 16. Germany PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 17. France PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 19. Italy PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 20. Russia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
Figure 24. China PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 25. Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 28. India PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
Figure 30. Brazil PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
Figure 33. Turkey PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 34. Israel PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 36. UAE PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 37. AbbVie PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Pfizer PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. AstraZeneca PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. GlaxoSmithKline PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Clovis Oncology PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Everest Pharmaceuticals PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)